Malignant urachal neoplasms: A population-based study and systematic review of literature

Mylonas, Konstantinos S.; O'Malley, P.; Ziogas, Ioannis A.; El-Kabab, Lamis; Nasioudis, Dimitrios

doi:10.1016/j.urolonc.2016.07.021

Cited by 54 publications

(79 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We observed that the most common histology was AC (80%), followed by UC (11%) and SCC (3%). In a study using the SEER database, the proportion of histological subtypes of MUT are quite similar to the present findings; that is, 81% in AC, 10% in UC and 3% in SCC . The present results regarding the distributions of age and sex among the patients with AC were also similar to those in other reports .…”

Section: Discussionsupporting

confidence: 91%

“…Bruins et al . reported 152 cases in the Netherlands in 2012, and Mylonas et al . reported 420 cases in Greece in 2017.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, Mylonas et al . reported that seven of 16 published studies between 1991 and 2016 were carried out in Eastern Asia . Although the proportion of MUTs among all bladder cancers might be more frequent in Asia, further investigations including population‐based studies or multi‐institutional studies are necessary in the future.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, they recommended the use of the Sheldon or Mayo staging system . However, the recent population‐based study of MUTs used the TNM staging system . In 2015, Dhillon et al .…”

Section: Discussionmentioning

confidence: 99%

“…Surgery is a standard of care for localized MUT, but the most appropriate care for advanced cases has not been established, as there are few data from case reports/case series. Until recently, there has been only limited information about the clinicopathological features of MUTs from a large population‐based study . Herein, to identify the clinicopathological features of MUT cases in Japan, we retrospectively analyzed the cases of the patients newly diagnosed with MUT in 2008–2009 and 2012–2015 using the HBCR from Japan’s nationwide DCCHs and other core cancer care hospitals.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Clinicopathological features of malignant urachal tumor: A hospital‐based cancer registry data in Japan

et al. 2019

View full text Add to dashboard Cite

Objectives To identify the clinicopathological features of malignant urachal tumor in Japan, and analyze the 5‐year overall survival of malignant urachal tumor patients. Methods We used the hospital‐based cancer registry data to extract malignant urachal tumor cases that were diagnosed in 2008–2009 and 2012–2015, histologically confirmed, and received the first course of treatment. We analyzed the 5‐year overall survival using the 2008–2009 cohort’s data. Results We identified 456 patients, and malignant urachal tumor accounted for 0.4% of all malignant bladder cancers. The median age was 61 years (range 2–97), and 66% were men. The most common histology was adenocarcinoma (80%), followed by urothelial carcinoma (11%) and squamous cell carcinoma (3%). The proportions of patients were: 19% Ta/Tis/T1N0M0, 55% T2–3N0M0, 13% T4/N+ and 13% M+. Regarding the initial treatment, the proportions of surgery alone were 79% and 33% in cases of T3 or less N0M0 and T4/N+, respectively. The proportion of combination therapy including surgery and chemotherapy were 13% and 44% in T2–3N0M0 and T4/N+, respectively. Radiation therapy was not common at any stage. In the 2008–2009 cohort, the 5‐year overall survival rate in Ta/Tis/T1N0M0, T2–3N0M0, T4/N+ and M+ were 60%, 64%, 63% and 12%, respectively. Conclusions Malignant urachal tumors are quite rare in Japan, and most of those without metastasis are likely to be treated by surgery alone, even at advanced stages. A standard of care must be established for malignant urachal tumor patients at advanced stages or with metastasis, as the prognosis of these patients can be poor.

show abstract

Section: Discussionsupporting

confidence: 91%

“…Bruins et al . reported 152 cases in the Netherlands in 2012, and Mylonas et al . reported 420 cases in Greece in 2017.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Therefore, they recommended the use of the Sheldon or Mayo staging system . However, the recent population‐based study of MUTs used the TNM staging system . In 2015, Dhillon et al .…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Clinicopathological features of malignant urachal tumor: A hospital‐based cancer registry data in Japan

et al. 2019

View full text Add to dashboard Cite

show abstract

Clinical outcomes and patterns of population‐based management of urachal carcinoma of the bladder: An analysis of the National Cancer Database

Dursun

Lim

Svatek³

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

show abstract

Relapsed urachal carcinoma responding to first‐line chemotherapy with capecitabine‐oxaliplatin plus bevacizumab

et al. 2023

View full text Add to dashboard Cite

IntroductionAdvanced urachal carcinoma has a poor prognosis; however, a standard systemic treatment has not been established. We treated a patient with relapsed urachal carcinoma with capecitabine‐oxaliplatin plus bevacizumab, a standard regimen for colon cancer, and obtained favorable responses.Case presentationA 47‐year‐old woman presented with hematuria. Under the diagnosis of non‐metastatic urachal carcinoma, an extended partial cystectomy was performed. Histopathological examination revealed adenocarcinoma with negative surgical margins and lymph nodes. Thirty‐two months postoperatively, lung metastases and local recurrence were confirmed, along with elevated carcinoembryonic antigen levels, and nine chemotherapy cycles were administered. Subsequently, the recurrent lesion regressed, and tumor marker levels normalized. Fourteen months after treatment discontinuation, the disease remained stable without progression.ConclusionThis is the first report of advanced urachal carcinoma treated with capecitabine‐oxaliplatin plus bevacizumab, demonstrating the potential of this treatment as first‐line chemotherapy for this disease.

show abstract

Malignant urachal neoplasms: A population-based study and systematic review of literature

Cited by 54 publications

References 31 publications

Clinicopathological features of malignant urachal tumor: A hospital‐based cancer registry data in Japan

Clinicopathological features of malignant urachal tumor: A hospital‐based cancer registry data in Japan

Clinical outcomes and patterns of population‐based management of urachal carcinoma of the bladder: An analysis of the National Cancer Database

Relapsed urachal carcinoma responding to first‐line chemotherapy with capecitabine‐oxaliplatin plus bevacizumab

Contact Info

Product

Resources

About